Cargando…

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

Ovarian cancer is the second most lethal gynecological cancer worldwide and while most patients respond to initial therapy, they often relapse with resistant disease. Human epidermal growth factor receptors (especially HER1/EGFR and HER2/ERBB2) are involved in disease progression; hence, strategies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonello, Maria, Sims, Andrew Harvey, Langdon, Simon Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372909/ https://www.ncbi.nlm.nih.gov/pubmed/30766749 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0062

Ejemplares similares

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Epidermal growth factor receptors (EGFR) in human ovarian cancer.
por: Owens, O. J., et al.
Publicado: (1991)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.
por: Bartlett, J. M., et al.
Publicado: (1996)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

The status of epidermal growth factor receptor in borderline ovarian tumours
por: Showeil, Rania, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
por: Siwak, Doris R., et al.
Publicado: (2010)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer
por: Schram, Alison M., et al.
Publicado: (2016)

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
por: Faller, Bryan A, et al.
Publicado: (2009)

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?
por: Lee, Jun Ah, et al.
Publicado: (2012)

Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment
por: Pandey, Manoj, et al.
Publicado: (2003)

Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
por: Chen, Chen (Amy), et al.
Publicado: (2015)

Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer
por: Li, Da, et al.
Publicado: (2013)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes
por: Maka, Vinayak V., et al.
Publicado: (2014)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
por: Siddiqui, Mohammad R., et al.
Publicado: (2019)

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated NDRG1-Driven Proliferation in Triple-Negative Breast Cancer
por: Mishra, Akanksha, et al.
Publicado: (2020)

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
por: Wykosky, Jill, et al.
Publicado: (2011)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Periungual Inflammation with Adapalene
por: Hachisuka, Junichi, et al.
Publicado: (2011)

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
por: Simon, Nathan, et al.
Publicado: (2016)

Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma
por: SONG, XIAOPING, et al.
Publicado: (2016)

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Epidermal growth factor receptor function in the human urothelium
por: Wasén, C., et al.
Publicado: (2018)

Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis
por: Moldan, Matthew M., et al.
Publicado: (2013)

Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors
por: Lupu, I, et al.
Publicado: (2015)

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma
por: Amirabadi, Amir, et al.
Publicado: (2021)

Nuclear epidermal growth factor receptor as a therapeutic target
por: Atwell, Benjamin, et al.
Publicado: (2023)

Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.
por: Rabiasz, G. J., et al.
Publicado: (1992)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
por: Yu, Jinfeng, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017)

The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review
por: AlMazmomy, Asim M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2ct198vul0f5q8g4bbt3qqelst